IRVINE, Calif., May 12, 2021 – Bioniz Therapeutics, Inc., (“Bioniz”), a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class peptide-based multi-cytokine inhibitors for the treatment of cancer and autoimmune diseases,…
IRVINE, Calif., April 5 , 2021 – Bioniz Therapeutics, Inc., (“Bioniz”), a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class peptide-based multi-cytokine inhibitors for the treatment of cancer and autoimmune…
Experienced drug developer, most recently at Almirall, to lead Bioniz’s clinical trials of novel, selective multi-cytokine inhibitors to treat immune-driven diseases caused by dysregulated cytokine signaling IRVINE, Calif., March 24,…
IRVINE, Calif., January 4, 2020 – Bioniz Therapeutics, Inc., (“Bioniz”), a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class peptide-based multi-cytokine inhibitors for the treatment of cancer and autoimmune diseases,…
– BNZ-1 showed an overall response rate (ORR) of 63.2% based on the Global Response Score (GRS) in a heavily pretreated, relapsed and refractory CTCL patient population –– No disease…
As a multi-cytokine inhibitor, BNZ-1 is a novel immuno-oncology drug that integrates inhibition of malignant cells, activation of tumor immunity, and suppression of inflammation IRVINE, Calif., November 5, 2020 –…
Irvine, California July, 2020– Bioniz Therapeutics, Inc., a clinical stage biopharmaceutical company developing first-in-class peptide therapeutics that selectively and simultaneously inhibit multiple cytokines to treat immuno-inflammatory diseases and cancers, today…
Irvine, CA, January, 2020 – Bioniz Therapeutics, Inc., a privately held clinical stage biopharmaceutical company developing first-in-class multi-cytokine peptide therapeutics for the treatment of immuno-inflammatory diseases and cancer, announced today…
— BNZ-1, a Novel Multi-Cytokine Inhibitor of IL-2/9/15, Demonstrates Favorable Safety and Robust Pharmacodynamic Activity – — Data to be Presented at Upcoming Scientific Meetings — –Bioniz to Continue BNZ-1…
Irvine, CA, April 4, 2018 — Bioniz Therapeutics, Inc., a clinical stage biopharmaceutical company developing first-in-class peptide therapeutics that selectively and simultaneously inhibit multiple cytokines to treat immuno-inflammatory diseases and…
After being named to In Vivo’s 2021 list of Rising Leaders, William Masters, a reporter for Scrip/Informa, interviewed Dr. Nazli Azimi. An excerpt of their conversation is below: Azimi knew…
Our founder and CEO, Nazli Azimi, PharmD, PhD, was named to In Vivo’s prestigious list of 2021 Rising Leaders. Marking the second edition of the ‘Rising Leaders’ list, In Vivo…
As 2018 came to a close, Life Science Leader interviewed industry leaders about what to expect in the coming years in biopharma. Our CEO and founder, Nazli Azimil, Pharm.D., Ph.D.,…
Bioniz Therapeutics is slated to start a Phase I trial for one of its cytokine inhibitors in partnership with the National Institutes of Health (NIH). Now, it’s nabbed a $13…
Privacy Policy
© 2021 Bioniz Theraputics. All Rights Reserved.
Website and Marketing: S3E, Digital Marketing Company Los Angeles
